Home » Stocks » LMNL

Liminal BioSciences Inc. (LMNL)

Stock Price: $5.15 USD -0.01 (-0.19%)
Updated Jan 25, 2021 2:10 PM EST - Market open
Market Cap 151.63M
Revenue (ttm) 3.74M
Net Income (ttm) -158.62M
Shares Out 16.06M
EPS (ttm) -9.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $5.15
Previous Close $5.16
Change ($) -0.01
Change (%) -0.19%
Day's Open 5.27
Day's Range 5.04 - 5.42
Day's Volume 595,947
52-Week Range 3.68 - 23.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: BJ, BLCM, QFIN, VCNX, VIVO
PRNewsWire - 1 month ago

LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, to...

Seeking Alpha - 2 months ago

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, ann...

PRNewsWire - 2 months ago

LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, tod...

PRNewsWire - 2 months ago

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, QC, and CAMBRIDGE, England, Nov. 8, 2020 /PRNewswire/ - Liminal BioS...

PRNewsWire - 2 months ago

LAVAL, QC and CAMBRIDGE, England, Nov. 6, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, toda...

PRNewsWire - 2 months ago

LAVAL, QC and CAMBRIDGE, England, Nov. 5, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, toda...

PRNewsWire - 4 months ago

- FDA assigns PDUFA target action date of March 5, 2021 LAVAL, QC and CAMBRIDGE, England, Sept. 21, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "C...

InvestorPlace - 4 months ago

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: ADMA, AZN, BNTX, CERS, PFE, SONN
Benzinga - 5 months ago

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...

Other stocks mentioned: ADMA, CERS, GRFS, KMDA, SONN, THMO, TTOO
Benzinga - 5 months ago

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the ...

Other stocks mentioned: KMDA, SONN
Seeking Alpha - 5 months ago

Liminal BioSciences: Under New Management And Chasing Ryplazim Approval

PRNewsWire - 5 months ago

LAVAL, QC, and CAMBRIDGE, England, Aug. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc.

Benzinga - 5 months ago

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Other stocks mentioned: BURG, KMDA
PRNewsWire - 6 months ago

LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical c...

PRNewsWire - 6 months ago

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical ...

PRNewsWire - 6 months ago

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical ...

PRNewsWire - 7 months ago

LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmace...

PRNewsWire - 7 months ago

LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmace...

About LMNL

Liminal BioSciences, a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. The Plasma Derived Therapeutics segment provides Plasma Pr... [Read more...]

Industry
Biotechnology
CEO
Kenneth Galbraith
Employees
300
Stock Exchange
NASDAQ
Ticker Symbol
LMNL
Full Company Profile

Financial Performance

In 2019, LMNL's revenue was 4.90 million, a decrease of -80.09% compared to the previous year's 24.63 million. Losses were -207.80 million, -25.90% less than in 2018.

Financial numbers in millions CAD.
Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for LMNL stock is "Buy." The 12-month stock price forecast is 10.15, which is an increase of 97.09% from the latest price.

Price Target
$10.15
(97.09% upside)
Analyst Consensus: Buy